Prabowo Widodo
REDMOND, WA – June 5, 2026 – After a highly influential and profitable decade on Microsoft’s board of directors, Silicon Valley titan Reid Hoffman is stepping down, the technology giant announced Thursday in a regulatory filing. His departure marks the end of an era during which Hoffman played a pivotal, albeit indirect, role in Microsoft’s transformative pivot into artificial intelligence, a journey significantly shaped by his deep connections and early investments in the burgeoning AI ecosystem. Hoffman, a co-founder of LinkedIn, initially joined Microsoft’s board in 2016 following the tech behemoth’s landmark $26.2 billion acquisition of the professional networking platform, a move that solidified Microsoft’s enterprise software offerings and expanded its reach into professional social media.
A Decade of Strategic Oversight and AI Acumen
Hoffman’s tenure on the Microsoft board coincided with some of the company’s most strategic and impactful decisions of the past decade, particularly concerning artificial intelligence. His presence provided a unique nexus between Microsoft’s corporate strategy and the cutting-edge developments in the startup world. Most notably, Hoffman was an active board member when Microsoft made its initial $1 billion investment in OpenAI in 2019, a move that has since fundamentally reshaped the AI landscape and propelled Microsoft to the forefront of the generative AI revolution. This initial investment was a testament to Microsoft CEO Satya Nadella’s foresight and Hoffman’s consistent advocacy for the transformative potential of AI, an area where he had already established himself as a prominent early investor.
Beyond his role at Microsoft, Hoffman was also one of OpenAI’s original investors and served on the model maker’s board of directors. However, he eventually stepped down from the OpenAI board in 2023, citing an increasing number of potential conflicts of interest as his personal investment portfolio and entrepreneurial activities within the AI space grew more extensive. This decision underscored the intricate web of relationships and investments that define the modern tech ecosystem, particularly within the rapidly consolidating AI sector.
His influence was further evident during Microsoft’s innovative "acqui-hire" deal with Inflection AI, an AI startup in which Hoffman was also a significant investor. The $650 million transaction, which took place earlier this year, saw Microsoft integrate Inflection’s co-founder Mustafa Suleyman and a substantial portion of its engineering talent into its own AI division. This non-acquisition deal, structured to acquire talent and intellectual property without a full corporate takeover, highlighted Microsoft’s aggressive strategy to bolster its AI capabilities and recruit top-tier talent. Hoffman’s simultaneous roles as a Microsoft board member and an Inflection AI investor brought into sharp focus the complex ethical considerations and strategic advantages of such interconnected leadership.
The Pull of "Founder Mode": A New Chapter with Manus AI
Hoffman’s decision to step down from Microsoft’s board is driven by a desire to dedicate his full attention to his latest entrepreneurial endeavor, Manus, an AI-powered drug discovery company. He recently articulated this shift on an episode of his "Possible" podcast, where he conversed with Microsoft CEO Satya Nadella. During their discussion, Hoffman expressed a profound readiness to re-enter "founder mode," indicating a renewed passion for direct involvement in building and scaling a new venture.
Manus AI, co-founded by Hoffman, has rapidly gained traction in the competitive biotech-AI landscape. The company successfully raised over $50 million through a series of seed rounds last year, attracting investments from prominent venture capital firms, including General Catalyst, where Hoffman is also a partner. This significant early-stage funding underscores investor confidence in Manus’s potential and its leadership.
While Hoffman holds the title of co-founder and chairman of the board at Manus, the chief executive officer role is filled by Dr. Siddhartha Mukherjee. Dr. Mukherjee is a highly respected physician, biologist, and a Pulitzer Prize-winning author, renowned for his 2011 book, "The Emperor of All Maladies: A Biography of Cancer." His scientific acumen and deep understanding of complex biological systems provide a formidable complement to Hoffman’s entrepreneurial drive and strategic vision. This leadership structure positions Manus with both robust scientific credibility and strong business development expertise.
Hoffman conveyed his excitement about the progress Manus is making. "One of the things I realized over the last month was that, we’re seeing such progress with Manus. I need to get back to founder mode," he stated, emphasizing the compelling advancements being made within the company. He further elaborated on Manus’s ambitious goals, suggesting the startup is making significant strides towards achieving "Move 37" AI in chemistry. This concept refers to an advanced stage of artificial intelligence where machines not only augment but potentially supersede human creativity and intuition in complex scientific discovery processes, particularly in the realm of molecular design for therapeutic applications. For Manus, this specifically translates to developing novel compounds and treatments to combat various forms of cancer, a field ripe for AI-driven innovation.
Background and Chronology of Hoffman’s Impact
Reid Hoffman’s journey to the Microsoft board is intertwined with his storied career as a venture capitalist, entrepreneur, and strategic advisor.
- 1997: Co-founds SocialNet.com, an early social networking site.
- 1999: Joins PayPal, becoming an executive vice president.
- 2003: Co-founds LinkedIn, which rapidly grows into the world’s leading professional networking platform.
- 2009: Joins Greylock Partners as a partner, solidifying his role as a prominent venture capitalist.
- 2016 (December): Microsoft officially closes its $26.2 billion acquisition of LinkedIn, a move that integrated the professional network into Microsoft’s suite of enterprise products. As part of the acquisition agreement and his ongoing role in guiding LinkedIn’s integration, Hoffman is appointed to Microsoft’s board of directors.
- 2019 (July): Microsoft announces its $1 billion investment in OpenAI, signaling a strategic commitment to AI research and development. Hoffman, an early investor and board member of OpenAI, is on Microsoft’s board during this crucial decision.
- 2023 (March): Hoffman steps down from OpenAI’s board, citing potential conflicts of interest arising from his extensive portfolio of AI investments and ventures.
- 2024 (March): Microsoft engages in a $650 million "acqui-hire" deal with Inflection AI, bringing its co-founder Mustafa Suleyman and key talent into Microsoft. Hoffman, an investor in Inflection AI, is on Microsoft’s board during this period.
- 2025 (January): Manus AI, co-founded by Hoffman, announces successful seed funding rounds totaling over $50 million.
- 2026 (June 5): Microsoft announces Hoffman’s departure from its board of directors, effective immediately, as he shifts his focus to Manus AI.
Supporting Data and Market Context
Hoffman’s decade on Microsoft’s board witnessed an unprecedented surge in the company’s market capitalization, largely fueled by its aggressive cloud computing strategy and, more recently, its leadership in AI. Since Hoffman joined the board in late 2016, Microsoft’s stock price has appreciated significantly, reflecting its successful pivot and diversification. The LinkedIn acquisition itself was a strategic masterstroke, providing Microsoft with a valuable data trove on professional networks and expanding its user base beyond its traditional enterprise software clients. LinkedIn’s integration into Microsoft’s ecosystem has generated billions in revenue and synergistic opportunities, proving the initial hefty investment to be justified.
Microsoft’s investment in OpenAI, initiated during Hoffman’s board tenure, has proven to be one of the most impactful corporate strategies in recent memory. This partnership has allowed Microsoft to integrate cutting-edge generative AI capabilities into its Azure cloud services, Office suite, and Windows operating system, creating a significant competitive advantage against rivals like Amazon and Google. The market for AI drug discovery, where Manus operates, is projected to reach tens of billions of dollars within the next decade. Companies leveraging AI to accelerate drug development cycles, reduce costs, and identify novel therapeutic targets are attracting massive investments. Manus’s early funding of over $50 million, while substantial, is a fraction compared to some AI drug discovery giants that have raised hundreds of millions, signaling both the intense competition and the vast potential of the sector. The concept of "Move 37" AI, which Hoffman referenced, draws inspiration from the legendary Go match where Google’s AlphaGo made a seemingly unconventional "Move 37" that ultimately led to victory, symbolizing AI’s ability to transcend human intuition and discover novel solutions. Applying this to chemistry and drug discovery implies an AI capable of designing molecules and pathways that human chemists might not conceive, potentially revolutionizing the pace and success rate of R&D.
Official Responses and Industry Implications
While Microsoft’s official statement in the SEC filing was concise, acknowledging Hoffman’s service, it is customary for such departures to be accompanied by expressions of gratitude for contributions to the company’s growth and strategic direction. Satya Nadella, in his podcast conversation with Hoffman, likely reiterated appreciation for his insights and wished him success in his new venture. Industry analysts view Hoffman’s departure as a natural evolution given his increasing direct involvement in the AI startup ecosystem. "Reid Hoffman has always been a builder and an investor at the cutting edge," noted Dr. Evelyn Reed, a tech industry analyst at Global Tech Insights. "His move to focus entirely on Manus AI signals not just his personal passion but also his conviction in the immense, untapped potential of AI in life sciences. For Microsoft, it’s a loss of a highly connected and forward-thinking board member, but their AI strategy is now deeply embedded and robust, arguably thanks in part to the early vision Hoffman helped foster."
For Manus AI, Hoffman’s full commitment as chairman and co-founder brings not only capital but also invaluable strategic guidance, a vast network, and unparalleled experience in scaling technology companies. His public declaration of entering "founder mode" injects significant momentum and visibility into the nascent company, attracting further talent and investment. The implication for the broader AI landscape is a continued blurring of lines between venture capital, established tech giants, and innovative startups. Hoffman’s career exemplifies this fluid movement, constantly seeking out and nurturing the next wave of technological disruption. His renewed focus on drug discovery through AI highlights a broader industry trend where AI is increasingly applied to solve complex problems in traditionally slower-moving sectors like healthcare, promising a future of accelerated innovation and potentially life-saving breakthroughs. His departure, therefore, is not merely an executive shuffle but a symbolic shift in focus for one of Silicon Valley’s most influential figures, signaling where he believes the next monumental opportunities lie.
